| This week's sponsor is Eli Lilly and Company. | |  | AHS 2018: Lilly Showcases Leadership in Migraine and Cluster Headache
For more than 50 years, Eli Lilly and Company has been committed to addressing the ongoing treatment challenges in neurology, primary headache disorders and chronic and recurrent pain. Learn more about Lilly's leadership in the development of innovative treatments for migraine and cluster headache here. |
Today's Rundown Featured Story | | | Friday, July 13, 2018 Human Longevity has let top executive Nino Fanlo go, FierceBiotech has learned. The CFO/COO departed months after he was implicated in a scandal that engulfed his former employer. |
|
|
Top Stories Friday, July 13, 2018 Amgen and UCB have refiled for FDA approval of osteoporosis drug romosozumab one year after the agency rejected a submission on safety grounds. The revised filing pools all the phase 3 data in a bid to show the sclerostin-targeting antibody has a positive risk-benefit profile. Friday, July 13, 2018 Celgene says it has raised the top dose and expanded its trial of its anti-BCMA CAR-T candidate for myeloma licensed from Bluebird Bio, but the company still thinks it’s on course for approval in 2020. Friday, July 13, 2018 Modus Therapeutics has raised over 140 million Swedish krona, or about $15.7 million, to advance clinical development of the company’s compound for sickle cell disease. Friday, July 13, 2018 Octave Biosciences picked up a pair of industry veterans for its board of directors, as well as a $14 million series A round that will advance its care management technology in multiple sclerosis. Thursday, July 12, 2018 In this week's EuroBiotech Report, Abingworth and Forbion raise $630 million, Dynacure bags €47 million for clinical push, Genmab inks a bispecific pact and more. Friday, July 13, 2018 Biogen and Eisai's anti-amyloid candidate makes landmark progress in Alzheimer's trial; Otsuka signs two M&A deals in antibody and renal denervation; Samsung BioLogics faces a criminal probe over its Biogen biosimilar joint venture agreement and more. Friday, July 13, 2018 Gilead's clinical research director is joining Nimbus to lead drug discovery, Immunocore’s CMO is jumping to Carl June's Tmunity, Kite has tapped an Eisai cancer vet to lead CAR-T sales, and Syntimmune has picked up a Vertex VP for CMO. Those moves plus more hirings, firings and retirings throughout the industry. | This week's sponsor is ExL Events. | | Can’t-miss interactive workshop at the industry's premier Safety Labeling & Packaging event!
This 3-day conference will provide attendees with the skills needed to understand how to develop & enhance an end-to-end process to ensure a compliant label for your drug packaging.
View the agenda and workshop details! Use Discount Code C1049FIERCE to save 15% |
Resources Sponsored by: Veeva See results from the Tufts eClinical Landscape Study – CRO Report on current data management practices, goals, and challenges for contract research organizations (CROs). Life Science Strategy Group Take this anonymous 10-minute survey to share your thoughts on leading eClinical technology solutions and earn up to $55 honoraria. Take the survey now! Sponsored by: Docusign Life science companies are experiencing a significant transformation in how they bring new products to market. |
|
